Novavax Inc NVAX shares have been halted since the pre-market session as the U.S. Food and Drug Administration holds a meeting to determine the fate of the company's COVID-19 vaccine.
A committee of independent FDA vaccination advisors have been assessing the safety of the company's vaccine on Tuesday at a FDA Advisory Committee meeting.
The committee aims to decide whether or not it should recommend the Novavax vaccine for adults in the U.S. Following the meeting, the FDA will make a final authorization decision. The Novavax vaccine has already been authorized in several countries outside the U.S. It would be the fourth COVID-19 vaccine to receive authorization in the U.S.
Novavax is a biotechnology company that works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.
See Also: Why Kiromic Biopharma Shares Are Skyrocketing Today
NVAX Price Action: Novavax shares have traded between $41.10 and $277.79 over a 52-week period.
The stock remained halted at press time, according to data from Benzinga Pro.
Photo: Maryland GovPics from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
